HC Wainwright Has Positive Outlook of CMPS FY2026 Earnings

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Compass Pathways in a research note issued on Monday, March 2nd. HC Wainwright analyst P. Trucchio now expects that the company will earn ($1.36) per share for the year, up from their previous estimate of ($2.00). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Compass Pathways’ FY2027 earnings at ($0.72) EPS, FY2028 earnings at $1.56 EPS and FY2029 earnings at $3.69 EPS.

CMPS has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Wednesday, January 21st. Morgan Stanley boosted their target price on Compass Pathways from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Royal Bank Of Canada upped their target price on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group increased their price target on Compass Pathways from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Compass Point set a $15.00 price objective on Compass Pathways in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.13.

Compass Pathways Stock Performance

Shares of CMPS opened at $6.78 on Thursday. The firm has a market capitalization of $651.00 million, a PE ratio of -2.49 and a beta of 1.90. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $6.98 and a 200 day moving average price of $6.13. Compass Pathways has a 52-week low of $2.25 and a 52-week high of $8.90.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Compass Pathways during the 4th quarter worth $47,000. Seven Fleet Capital Management LP purchased a new stake in shares of Compass Pathways during the fourth quarter valued at $276,000. Corient Private Wealth LLC boosted its position in shares of Compass Pathways by 3.2% in the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after purchasing an additional 1,200 shares during the period. XTX Topco Ltd boosted its position in shares of Compass Pathways by 457.5% in the 4th quarter. XTX Topco Ltd now owns 56,786 shares of the company’s stock valued at $392,000 after purchasing an additional 46,600 shares during the period. Finally, Virtus Investment Advisers LLC increased its stake in Compass Pathways by 56.8% in the 4th quarter. Virtus Investment Advisers LLC now owns 39,471 shares of the company’s stock worth $272,000 after purchasing an additional 14,297 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

Key Headlines Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright substantially raised multi-year EPS forecasts (FY2026–FY2029/FY2030) and reiterated a “Buy” rating with a $70 price target, projecting a path from near-term losses to meaningful profitability in later years — a bullish research-note catalyst that can support higher valuation expectations. HC Wainwright Forecasts Strong Price Appreciation for Compass Pathways (NASDAQ:CMPS) Stock
• Neutral Sentiment: Short-interest reports in early March show “0 shares” and NaN changes with a reported days-to-cover of 0.0 — this appears to be a data anomaly and therefore provides little reliable information about bearish positioning or short-covering dynamics at present.
• Negative Sentiment: Despite HC Wainwright’s bullish revisions, the consensus earnings estimate remains negative (current-year consensus ~($2.33) EPS) and the company is not yet profitable. That gap between an upbeat outlier forecast and market consensus raises execution and timing risk; investors may be selling into the analyst headlines until clearer, near-term operational progress is visible.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.